Kanamycin: Uses, Dosage, Side Effects, and Precautions

Introduction

Kanamycin is an aminoglycoside antibiotic used to treat severe bacterial infections, particularly those caused by gram-negative bacteria. It was originally isolated from the bacterium Streptomyces kanamyceticus. Kanamycin works by binding to the bacterial 30S ribosomal subunit, causing misreading of t-RNA and inhibiting protein synthesis.

Classification

Kanamycin belongs to the aminoglycoside class of antibiotics. Its primary active component is kanamycin A, which has the molecular formula C ₁₈H ₃₆N ₄O ₁₁. Kanamycin is identified by the CAS number 59-01-8 and the PubChem CID 6032.

Mechanism of Action

The mechanism of action of kanamycin involves binding to the 30S ribosomal subunit of susceptible bacteria. This interaction causes misreading of the genetic code during translation, leading to the production of non-functional or toxic proteins. Ultimately, this process disrupts bacterial growth and leads to cell death.

Clinical Uses

Kanamycin is primarily used to treat severe bacterial infections caused by susceptible gram-negative bacteria, such as Escherichia coli, Proteus species, and Acinetobacter species. It is also used as a second-line agent in the treatment of tuberculosis. Kanamycin is administered through intramuscular or intravenous injection.

Dosage and Administration

The dosage of kanamycin depends on factors such as the severity of the infection, the patient’s age, and renal function. In adults, the usual dose ranges from 15 to 30 mg/kg/day, divided into two or three doses. Dosage adjustments may be necessary for patients with impaired renal function. It is crucial to monitor serum kanamycin levels to ensure therapeutic efficacy and minimize the risk of toxicity.

Side Effects and Precautions

Common side effects of kanamycin include injection site reactions, nausea, vomiting, and diarrhea. More serious adverse effects include nephrotoxicity and ototoxicity, which can lead to permanent kidney damage and hearing loss, respectively. Patients with pre-existing renal impairment, auditory disorders, or those receiving other nephrotoxic or ototoxic drugs are at increased risk of these complications. Regular monitoring of renal function and auditory function is essential during kanamycin therapy.

Drug Interactions

Kanamycin may interact with other medications, including loop diuretics, vancomycin, and other aminoglycosides. These interactions can potentiate the risk of nephrotoxicity and ototoxicity. Concurrent use of kanamycin with neuromuscular blocking agents may enhance their effects, leading to prolonged respiratory paralysis. Patients should inform their healthcare provider about all medications they are taking before starting kanamycin therapy.

Resistance and Spectrum of Activity

Bacterial resistance to kanamycin can occur through various mechanisms, such as enzymatic inactivation, altered target sites, or reduced drug accumulation. The emergence of resistant strains has limited the use of kanamycin in recent years. However, it remains effective against a broad spectrum of gram-negative bacteria, including some strains resistant to other antibiotics.

Conclusion

Kanamycin is a potent aminoglycoside antibiotic used to treat severe bacterial infections caused by susceptible gram-negative bacteria. While it has been a valuable tool in the fight against infectious diseases, its use is limited by the potential for serious side effects and the emergence of resistant strains. Careful monitoring and appropriate use are essential to ensure the safe and effective use of kanamycin in clinical practice.

References

1. Krause, K. M., Serio, A. W., Kane, T. R., & Connolly, L. E. (2016). Aminoglycosides: An Overview. Cold Spring Harbor Perspectives in Medicine, 6(6), a027029.
2. Yadav, R., Bulitta, J. B., & Landersdorfer, C. B. (2020). Pharmacometrics-guided dosing of aminoglycosides. Clinical Pharmacokinetics, 59(11), 1359-1371.
3. Selimoglu, E. (2007). Aminoglycoside-induced ototoxicity. Current Pharmaceutical Design, 13(1), 119-126.